Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

Not Applicable

Completed

• Conditions: Central Retinal Vein Occlusion With Macular Edema
• Interventions: Drug: Group A

• Registration Number: NCT04812977
• Lead Sponsor: Hayatabad Medical Complex

Brief Summary

To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-06-10
• Primary Completion: 2018-12-10
• Study Completion: 2018-12-10
• Study First Submitted: 2021-03-20
• Study First Submitted QC: 2021-03-20
• Study First Posted: 2021-03-24
• Results First Submitted: 2021-05-30
• Status Verified: 2022-04
• Results First Submitted QC: 2022-04-03
• Last Update Submitted: 2022-04-03
• Results First Posted: 2022-10-03
• Last Update Posted: 2022-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.

Exclusion Criteria

• previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Group A	A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.
Group B	Group A	Intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.

Primary Outcome Measures

Name	Time	Method
Visual Acuity	Baseline and 6 months	Change in visual acuity

Secondary Outcome Measures

Name	Time	Method
Central Foveal Thickness	Baseline and 6 months	change in central foveal thickness

Trial Locations

Locations (1)

Hayatabad Medical Complex; 🇵🇰 Peshawar, KPK, Pakistan